Cited by 405CRISPR and Genetic EngineeringChromatin Remodeling and CancerCancer Genomics and Diagnostics

Applications of the CRISPR-Cas9 system in cancer biology

Open access
Sánchez-Rivera, Francisco J., Jacks, Tyler·2015·Nature Reviews Cancer

Abstract

The prokaryotic type II CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) system is rapidly revolutionizing the field of genetic engineering, allowing researchers to alter the genomes of a large range of organisms with relative ease. Experimental approaches based on this versatile technology have the potential to transform the field of cancer genetics. Here, we review current approaches for functional studies of cancer genes that are based on CRISPR-Cas, with emphasis on their applicability for the development of next-generation models of human cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3950

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus.

    “In addition, CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus [52–55].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [75]Blasco RB Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology Cell Rep 2014 9 1219 1227 25456124

Cited by

Sorted by citations

Authors
Sánchez-Rivera, F. J., & Jacks, T.
Affiliations
Howard Hughes Medical Institute (US)
Corresponding author
Jacks, Tyler
Venue
Nature Reviews Cancer
Published
2015-06-04
Volume
15
Issue
7
Pages
387-393
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W1692777765
Cited by
405
References
86
Citations by year
2026: 19 · 2025: 21 · 2024: 21 · 2023: 33 · 2022: 45 · 2021: 43 · 2020: 34 · 2019: 40 · 2018: 48 · 2017: 48 · 2016: 39 · 2015: 12 · 2014: 1
FWCI
4.75
Type
journal article
Language
en
Open access
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
  • PMC
Funders
  • U.S. Department of Defense
  • Howard Hughes Medical Institute
  • CYTED Ciencia y Tecnología para el Desarrollo
  • National Institutes of Health
  • National Cancer Institute (P30CA014051)
  • National Institute of General Medical Sciences (T32GM007287)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
CRISPR/Cas9, tumor models, cancer genetics, genome editing, cancer therapeutics, tumor evolution, genetic alterations
MeSH terms
Animals, Endonucleases, Genetic Engineering, Humans, Models, Genetic, Neoplasms, Streptococcus pyogenes, Genes, p53, RNA Interference, Genes, Neoplasm, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review